Curcuwin Ultra+, OmniActive Health Technologies’ (“OmniActive” or “the Company”) latest addition to the company’s branded, highly bioavailable curcumin portfolio, was the subject of new science with the publication of “Superior Bioavailability of a Novel Curcumin Formulation in Healthy Humans Under Fasting Conditions” in Advances in Therapy. The study will also be presented during this year’s Experimental Biology (EB) meeting in Philadelphia, PA, from April 2-5.
“OmniActive continues to champion innovation and invest in science for the betterment of human nutrition,” said Deshanie Rai, PhD, FACN, VP, Global Scientific and Regulatory Affairs at OmniActive. “Having our data selected to be presented at the prestigious EB meeting and accepted for publication in the well-respected peer-reviewed journal Advances in Therapy speaks to the strength and relevance of this new science.”
In an acute dose, randomized, double-blind, three treatment, crossover oral bioavailability study involving 24 healthy male and female volunteers between 18 and 55 years, subjects received a single dose of Curcuwin Ultra+ 250 mg, Curcuwin Ultra+ 500 mg and 1800 mg of a 95% turmeric extract. The study showed that 250 mg Curcuwin Ultra+ was 144x more bioavailable compared to standard curcumin. In other words, this translates to one capsule containing 250 mg of Curcuwin Ultra+ being equal to 30 capsules containing the standard 95% curcumin extract. Curcuwin Ultra+ was also shown to absorb 40% faster than standard curcumin.
Curcuwin Ultra+ was developed by OmniActive to bring a clinically studied, highly bioavailable lower dose curcumin aimed at supporting joint and general health benefits for on-the-go lifestyles. Curcuwin Ultra+, which will be commercially available midyear, was first introduced at SupplySide West 2021 and was a well-received innovation in the curcumin space. Those interested in discussing Curcuwin Ultra+ are welcome to meet during EB or are encouraged to contact us at info@omniactives.com.
About OmniActive
Established in 2005, OmniActive seeks to improve lives through innovative science and natural health solutions. OmniActive’s product portfolio consists of scientifically validated, IP-protected, branded Specialty Actives and an extensive line of natural Botanical Actives for global customers in the dietary supplement, functional food, and beverage markets.
The Company’s leading brands include Lutemax 2020, Lutemax Free Lutein and Lutein Esters, Lutemax Skinglo, Capsimax, Curcuwin, Curcuwin Ultra+, enXtra, Gingever, Nutritears, Xtenergy, and Omnixan. OmniActive partners with customers through its sales and distribution networks in key markets worldwide, supported by three global R&D centers and best-in-class production facilities throughout India. The Company has offices in Mumbai, India and Morristown, New Jersey.
Advances in Therapy is an international, open choice, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad, covering theuse of therapies, devices, and surgical techniques across all therapy areas.
Experimental Biology (EB) is the annual meeting of five societies that explores the latest research in anatomy, biochemistry and molecular biology, investigative pathology, pharmacology, and physiology. Participants represent scientists from academic institutions, government agencies, nonprofit organizations, and industry.
The meeting features plenary lectures, workshops, symposia, posters presentations, on-site career services and exhibits spotlighting products and services integral to this professional community.
Media contacts
Sabrina Di Blasio
OmniActive
+1 514-258-8183
sabrina@omniactives.com
Becky Wright
Wright on Marketing
+1 201-675-0197
becky@wrightonmarketing.com
Media Contact
Company Name: OmniActive
Contact Person: Sabrina Di Blasio
Email: Send Email
Phone: +1 514-258-8183
Country: United States
Website: https://omniactives.com/
